Lilly Acquires Ventyx Biosciences for $1.2 Billion to Expand Inflammation Treatment Pipeline
Eli Lilly acquires Ventyx Biosciences for $1.2 billion to advance oral therapies targeting chronic inflammation in heart, brain, and autoimmune diseases.
/ 3 items
#VTYX↓
Pharma Stock Moves: Oppenheimer Downgrades Rhythm, New Buys on Vanda, Verrica, CervoMed, and Ventyx
Oppenheimer downgrades Rhythm Pharmaceuticals after major gains, while analysts issue fresh Buy ratings on Vanda, Verrica, CervoMed, and Ventyx highlighting key catalysts and growth potential.
Oral VTX3232 Study Reveals Significant Reductions in Inflammatory Cardiovascular Risk Markers
Ventyx Biosciences' VTX3232 demonstrates significant reduction in heart disease risk markers in Phase 2 trial, with strong anti-inflammatory effects and good safety profile.